All the news

The experimental caspase inhibitor emricasan did not meet the statistical threshold for improvement of portal hypertension in people with non-alcoholic steatohepatitis (NASH), but it did appear to have some benefit for those at ...

Now that hepatitis C can be successfully treated, non-alcoholic fatty liver disease (NAFLD) is becoming an increasingly important cause of serious liver problems and liver-related death among people living with HIV in the ...

Obeticholic acid (Ocaliva) led to a significant improvement in liver fibrosis related to non-alcoholic steatohepatitis (NASH), offering a potential future option for an increasingly common liver disease with no good current therapies, researchers ...